Physician profile
Charles Mount
NPI 1598962078
$188,942.51
in general payments reported to CMS, 2019-2025
29 companies · $16K in 2025
The $16K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $16K · 2021: $4,751 · 2022: $41K · 2023: $39K · 2024: $21K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Food and Beverage: $8,595 · Consulting Fee: $1,180 · Education: $148 · Travel and Lodging: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,712.50 |
| Food and Beverage | $8,595.40 |
| Consulting Fee | $1,180.00 |
| Education | $148.08 |
| Travel and Lodging | $111.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $139,192.99 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $24,340.61 | 2019-2025 | |
| Celgene Corporation | $12,160.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $2,818.36 | 2019-2024 | Dupixent |
| Ucb, INC. | $2,178.83 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $2,134.21 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $2,031.57 | 2020-2023 | Otezla |
| Galderma Laboratories, L.P. | $752.13 | 2023-2025 | Aklief, Epsolay, Twyneo |
| Genzyme Corporation | $668.40 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $609.92 | 2022-2024 | Sotyktu |
| Astrazeneca Pharmaceuticals Lp | $528.05 | 2021-2025 | Saphnelo |
| Journey Medical Corporation | $445.72 | 2022-2025 | |
| Incyte Corporation | $220.28 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.80 | 2024 | Jublia, Duobrii, Cabtreo |
| Arcutis Biotherapeutics, INC. | $112.11 | 2024 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $95.25 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $83.87 | 2023 | Dupixent |
| Leo Pharma INC. | $78.21 | 2023-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $73.63 | 2023-2025 | Blu-U, Odomzo, Winlevi |
| Dermavant Sciences, INC. | $44.87 | 2022-2023 | Vtama |
| Lilly USA, LLC | $41.71 | 2023-2024 | Ebglyss, Taltz |
| Merck Sharp & Dohme LLC | $37.18 | 2023-2025 | Keytruda |
| Janssen Scientific Affairs, LLC | $30.99 | 2021 | |
| Pfizer INC. | $28.79 | 2022-2023 | |
| Aurinia Pharma U.S., INC. | $26.19 | 2022 | |
| Organon LLC | $22.67 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.56 | 2024 | |
| Integra Lifesciences Corporation | $22.31 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Helsinn Therapeutics (U.S.), INC. | $18.59 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mount listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.